Literature DB >> 3738853

Bromocriptine induced pleuropulmonary fibrosis.

J Wiggins, C Skinner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3738853      PMCID： PMC460321          DOI： 10.1136/thx.41.4.328

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  8 in total

1.  Some aspects of receptor pharmacology of ergotamine.

Authors:  H O Schild
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

2.  Pleuropulmonary shadows on bromocriptine.

Authors:  G M Besser; J A Wass
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

3.  Pleuropulmonary changes during long-term bromocriptine treatment for Parkinson's disease.

Authors: 
Journal:  Lancet       Date:  1981-01-03       Impact factor: 79.321

4.  Cardiac and pulmonary fibrosis during methysergide therapy for headache.

Authors:  J R Graham
Journal:  Am J Med Sci       Date:  1967-07       Impact factor: 2.378

5.  [Pleuropulmonary fibrosis and bromocriptine].

Authors:  J Vergeret; M Barat; A Taytard; P Bellvert; P Domblides; J J Douvier; P Fréour
Journal:  Sem Hop       Date:  1984-03-08

6.  Pleural effusion and fibrosis during treatment with methysergide.

Authors:  W Hindle; E Posner; M T Sweetnam; R S Tan
Journal:  Br Med J       Date:  1970-03-07

7.  Bromocriptine in the long-term management of advanced Parkinson's disease.

Authors:  J D Grimes; M N Hassan
Journal:  Can J Neurol Sci       Date:  1983-05       Impact factor: 2.104

8.  Recent advances in the treatment of Parkinson's disease: the role of bromocriptine.

Authors:  P A Le Witt; D B Calne
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575
  8 in total
  2 in total

1.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

2.  Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes.

Authors:  Michael A Via; Himani Chandra; Takako Araki; Matthew V Potenza; Maria Skamagas
Journal:  Diabetes Metab Syndr Obes       Date:  2010-03-26       Impact factor: 3.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.